Company intelligence / Profile preview

CERES BRAIN Therapeutics

Paris, Île-de-France, Franceceres-brain.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Ceres Brain Therapeutics is developing CBT101, a patented intranasal creatine prodrug designed to bypass the defective or absent creatine transporter in patients with CTD. Animal studies have shown significant improvements in cognitive behavior. The company is preparing for its first clinical trial and holds a portfolio of six patents related to its platform technology.[8][9]

Therapeutic areas: Rare DiseasesNeurology
Modalities: Small molecule prodrugs (specifically creatine prodrugs)[5][9]
Industry: Biotech

Drug pipeline

2 assets

CBT-201

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), France – R&D collaboration and patent co-holding institution.[1][8]

Beyond the preview

Go deeper on CERES BRAIN Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CERES BRAIN Therapeutics.

Explore the full profile